During the last session, Leap Therapeutics Inc (NASDAQ:LPTX)’s traded shares were 0.42 million, with the beta value of the company hitting 0.32. At the end of the trading day, the stock’s price was $0.50, reflecting an intraday loss of -0.85% or -$0.01. The 52-week high for the LPTX share is $4.79, that puts it down -858.0 from that peak though still a striking 4.0% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $19.31M, and the average intraday trading volume over the past 10 days was 0.95 million shares, and the average trade volume was 784.57K shares over the past three months.
Leap Therapeutics Inc (LPTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. LPTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.38.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Leap Therapeutics Inc (LPTX) registered a -0.85% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.85% in intraday trading to $0.50, hitting a weekly high. The stock’s 5-day price performance is -1.04%, and it has moved by -84.50% in 30 days. Based on these gigs, the overall price performance for the year is -83.86%. The short interest in Leap Therapeutics Inc (NASDAQ:LPTX) is 3.21 million shares and it means that shorts have 2.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 90.91% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5.5 and $5.5 respectively. As a result, LPTX is trading at a discount of -1000.0% off the target high and -1000.0% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.36%. While earnings are projected to return 53.39% in 2025, the next five years will return 32.44% per annum.
LPTX Dividends
Leap Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Leap Therapeutics Inc insiders own 17.29% of total outstanding shares while institutional holders control 43.21%, with the float percentage being 52.24%.
Also, the Mutual Funds coming in first place with the largest holdings of Leap Therapeutics Inc (LPTX) shares are Simplify Exchange Traded Fds-Health Care ETF and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Simplify Exchange Traded Fds-Health Care ETF owns about 1.06 shares. This amounts to just over 2.76 percent of the company’s overall shares, with a $0.53 million market value. The same data shows that the other fund manager holds slightly less at 754.74, or about 1.97% of the stock, which is worth about $0.38 million.
